For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39130 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other juri ...

8 INVESTOR PRESENTATION August 2022 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future results of operations, business strategies, development plans, regulatory activities, market opportunity competitive position, potential growth opportunities ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdict ...

TELA Bio, Inc. (NASDAQ:TELA) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Louisa Smith – Gilmartin Group Tony Koblish – President and Chief Executive Officer Roberto Cuca – Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Caitlin Cronin – Canaccord Matthew O'Brien – Piper Sandler Dave Turkaly – JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarte ...

TELA Bio, Inc. (NASDAQ:TELA) Q1 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Louisa Smith - Investor Relations Antony Koblish - President and Chief Executive Officer Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Zachary Weiner - Jefferies David Turkaly - JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a remi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37526 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdic ...

Table of Contents ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) For the transition period from to Commission file number: 001-37526 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction ...

Financial Data and Key Metrics Changes - TELA Bio reported fourth quarter revenue of $8.4 million, a 9% increase from the third quarter and a 48% increase from Q4 2020 [5][14] - Full year revenue for 2021 was $29.5 million, reflecting a growth of 62% from 2020 [5][17] - Gross profit for Q4 2021 was $5.7 million, with a gross profit percentage of 68%, up from 65% in Q4 2020 [14] - The net loss for Q4 2021 was $8.6 million, compared to $7.8 million in the same period in 2020 [16] Business Line Data and Key Metrics Changes - Sales for the PRS franchise increased by 90% in 2021 compared to 2020 [11] - In Q4 2021, 57% of OviTex hernia repairs were performed using laparoscopic or robotic surgeries, indicating a shift towards robotic-assisted procedures [10] Market Data and Key Metrics Changes - The company anticipates year-over-year revenue growth in 2022 of approximately 44%, assuming no greater COVID-related disruptions than in 2021 [6] - The impact of the Omicron variant affected procedures and performance in December, leading to lower-than-expected revenues in early 2022 [5][18] Company Strategy and Development Direction - TELA Bio is evolving from a focus on high-quality reinforcement materials to prioritizing soft tissue reconstruction solutions and complementary technologies [8] - The company plans to leverage its sales force to expand its total addressable market with additional synergistic products [9] - TELA Bio aims to become a market leader in soft tissue preservation and restoration, supported by innovative products and compelling clinical data [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong performance in Q4 2021 despite COVID-19 headwinds [20] - The company expects to maintain durable growth and increasing market penetration in 2022 [20] - Management noted that the market is rebounding, and they anticipate capturing backlog as the year progresses [46] Other Important Information - TELA Bio ended Q4 2021 with $43.9 million in cash and cash equivalents [16] - The company has trained over 300 physicians on its products, which is expected to drive adoption [12] Q&A Session Summary Question: Guidance for 2022 revenue range - Management explained that the guidance range of $40 million to $45 million includes assumptions about COVID-19 impacts and sales rep productivity [24][25] Question: Sales rep productivity and expansion - Management expressed confidence in sales rep productivity, noting that the Playbook90 methodology has accelerated productivity and shortened the time for reps to become profitable [28][29] Question: Overall headcount and operating expenses - Management indicated plans to increase headcount to approximately 175 employees, focusing on commercialization and product portfolio expansion [33][34] Question: Data from clinical trials - Management provided updates on the BRAVO studies, indicating that final write-ups and publications are expected within the next few months [42][43] Question: Gross margin expectations for 2022 - Management indicated that gross margin is expected to stabilize at the higher end of the range seen in 2021 due to prior inventory adjustments [44] Question: Backlog recapture opportunities - Management acknowledged that while backlog has not yet been realized, they expect it to materialize as the year progresses [46] Question: SiteGuard product usage and margin profile - Management confirmed that SiteGuard will initially be used in plastic surgery and has a lower margin profile compared to other products, but it is expected to drive usage of other products [49][50]

TELA Bio, Inc. (NASDAQ:TELA) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Hannah Jeffrey - The Gilmartin Group Tony Koblish - President and Chief Executive Officer Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Andrew Stafford - Piper Sandler Frank Pinal - Jefferies Kyle Rose - Canaccord Genuity David Turkaly - JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2021 E ...

Financial Performance - Revenue for Q3 2021 was $7,654,000, representing a 44% increase from $5,313,000 in Q3 2020[18] - Gross profit for the nine months ended September 30, 2021, was $13,154,000, up from $7,572,000 in the same period of 2020, indicating a 74% increase[18] - Total operating expenses for Q3 2021 were $11,819,000, compared to $10,150,000 in Q3 2020, reflecting a 16% increase[18] - Net loss for Q3 2021 was $8,266,000, compared to a net loss of $7,703,000 in Q3 2020, showing an increase in loss of 7%[18] - For the nine months ended September 30, 2021, the company reported a net loss of $24.657 million, compared to a net loss of $21.004 million for the same period in 2020, representing an increase in loss of approximately 17%[27] - Total revenue for the nine months ended September 30, 2021, was $21.089 million, a 68.5% increase from $12.546 million in the same period of 2020[44] - Revenue increased by $2.3 million, or 44%, from $5.3 million for the three months ended September 30, 2020, to $7.7 million for the same period in 2021[91] - The net loss for the three months ended September 30, 2021, was $8.3 million, an increase of $0.6 million, or 7%, from $7.7 million for the same period in 2020[91] Cash and Assets - Cash and cash equivalents decreased to $53,636,000 as of September 30, 2021, down from $74,394,000 at the end of 2020, a decline of 28%[16] - Total assets decreased to $68,809,000 as of September 30, 2021, from $86,458,000 at the end of 2020, a reduction of 20%[16] - Cash and cash equivalents at the end of the period were $53.636 million, down from $81.467 million at the end of the same period in 2020, indicating a decrease of 34.1%[27] - The company reported a net decrease in cash and cash equivalents of $20.8 million for the nine months ended September 30, 2021[141] Liabilities and Deficits - Total liabilities increased to $41,080,000 as of September 30, 2021, compared to $37,432,000 at the end of 2020, an increase of 7%[16] - Accumulated deficit increased to $221,310,000 as of September 30, 2021, from $196,653,000 at the end of 2020, reflecting a 12% increase[16] - The company has an accumulated deficit of $221.3 million as of September 30, 2021[91] - The company anticipates incurring additional losses until it can generate sufficient revenue from its products to cover expenses[31] Research and Development - Research and development expenses for the nine months ended September 30, 2021, were $5,018,000, up from $3,092,000 in the same period of 2020, a 62% increase[18] - Research and development expenses increased by $0.2 million, or 17%, to $1.4 million for the three months ended September 30, 2021, driven by increased testing and development expenses[119] Product Performance - Revenue from OviTex for the nine months ended September 30, 2021, was $16.500 million, up 54.3% from $10.707 million in 2020[44] - The company recognized revenue from OviTex PRS of $4.589 million for the nine months ended September 30, 2021, compared to $1.839 million in 2020, representing a significant growth of 149.5%[44] - Unit sales of OviTex increased by 62% to 5,341 units for the nine months ended September 30, 2021, compared to 3,300 units in the same period of 2020[125] - The OviTex product line is used by more than 380 hospital accounts in the U.S.[84] - The recurrence rate for ventral hernias treated with OviTex is 2.7% at 12 months and remains below 5% at 24 months[83] Operating Activities - The company reported a net cash used in operating activities of $20.844 million for the nine months ended September 30, 2021, compared to $17.352 million in 2020, an increase of 20.5%[27] - Cash used in operating activities for the nine months ended September 30, 2021, was $20.8 million, compared to $17.4 million for the same period in 2020, reflecting an increase of 14.0%[142][143] Expenses - Total operating expenses for the nine months ended September 30, 2021, increased by $8.9 million, or 34%, to $34.9 million, reflecting higher sales and marketing, general and administrative, and research and development costs[123] - Sales and marketing expenses rose by $0.6 million, or 10%, to $6.9 million for the three months ended September 30, 2021, attributed to higher travel and consulting expenses[117] - General and administrative expenses increased by $0.9 million, or 33%, to $3.5 million for the three months ended September 30, 2021, due to higher professional and consulting expenses[118] Financing and Credit Facilities - The company has a credit facility with OrbiMed consisting of up to $35.0 million, with $30.0 million already borrowed[147] - The OrbiMed Term Loans bear interest at a rate of 7.75% plus the greater of one-month LIBOR or 2.0%, with a maturity date of November 16, 2023[149] - The Company must maintain a minimum cash balance of $2.0 million under the OrbiMed Credit Facility[60] Future Outlook - The company expects to incur losses for the foreseeable future due to ongoing uncertainties from the COVID-19 pandemic[91] - The company plans to continue investing in its commercial organization by hiring additional account managers and clinical development specialists[88] - The company is exploring new packaging technology to increase the shelf life of OviTex products[89]